Key result
Right ventricular dysfunction in patients with functional mitral regurgitation treated with MitraClip improved at 6 months (TAPSE 15 vs 19 mm, p=0.007) and did not affect the composite endpoint.
Why the study?
Does MitraClip implantation improve right ventricular function and clinical outcomes in high surgical risk patients with functional mitral regurgitation and baseline right ventricular dysfunction?
Cohort (n=60)
Does MitraClip implantation improve right ventricular function and clinical outcomes in high surgical risk patients with functional mitral regurgitation and baseline right ventricular dysfunction?
Successful MitraClip implantation in patients with functional mitral regurgitation and baseline right ventricular dysfunction significantly improves RV function at 6 months.
No takes yet. Share an insight, caveat, or question.
May support RV recovery after MitraClip in functional MR with baseline dysfunction; leaves open outcome benefits pending randomized data.
Godino et al. (2016) conducted a cohort in Moderate-severe functional mitral regurgitation (n=60). Right ventricular dysfunction vs. No right ventricular dysfunction was evaluated on Freedom from composite efficacy endpoint. Right ventricular dysfunction in patients with functional mitral regurgitation treated with MitraClip improved at 6 months (TAPSE 15 vs 19 mm, p=0.007) and did not affect the composite endpoint.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: